GPRC5D

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

Retrieved on: 
Monday, January 29, 2024
The Lancet, Hope, CMC, Patient, ISS, MRD, Therapy, GPRC5D, ASCO, EMD, CRS, IND, Food, Multiple myeloma, EHA, FDA, Investigational New Drug, BCMA, POLARIS, NMPA, Pharmaceutical industry

OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.

Key Points: 
  • OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D.
  • The therapy leverages Oricell's proprietary platforms including Ori®Ab antibodies, Ori®CAR construct and unique CMC know-how to achieve optimal binding and superior persistence and anti-tumor efficacy out of rejuvenated CAR-T cells.
  • The IND enables Oricell to initiate the clinical development for OriCAR-017 in the US immediately.
  • "The evidenced superior safety, efficacy and durability profile of OriCAR-017 is truly exciting and will significantly benefit multiple myeloma patients on a global scale.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, December 11, 2023
Patient, CIITA, Canadian Aviation Regulations, Treatment, Immune system, GPRC5D, HIP, IND, Biotechnology, CD47, Graft-versus-host disease, MD, Society, Therapy, ASH, B2M, Dose, Escape Room, CD22, Cytolysis, Multiple myeloma, Vaccine

SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology were presented at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

Key Points: 
  • “HIP-modified allogeneic CAR T cells remain well-tolerated in preclinical models.
  • CD22 HIP CAR T cells were well tolerated with no signs of graft-versus-host disease (GvHD).
  • Sana submitted the investigational new drug (IND) application and intends to begin human testing of SC262 in early 2024.
  • Additionally, these GPRC5D CAR T cells controlled multiple myeloma tumor cells both in vitro and in vivo, demonstrating efficacy that is on par with clinical benchmark GPRC5D CAR T cells.

Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Dexamethasone, ASH, CRS, Patient, Cell, Infection, Bortezomib, B-cell maturation antigen, GPRC5D, Carfilzomib, Therapy, Bristol Myers Squibb, ORR, Cancer, Diagnosis, Anemia, International Myeloma Foundation, CD3, Cytokine release syndrome, Haematopoietic system, Multiple myeloma, Immunomodulatory imide drug, Safety, Immune system, Incidence, Aes, DOR, Science, Hook effect, Public, Drug discovery, Society, Estate (law), Lenalidomide, Proteasome inhibitor, Thrombocytopenia, PFS, BMY, Daratumumab, Neutropenia, Partnership, Skin, Life, Mezi proudy, Research, NYSE, Disease, MRD, Translational Genomics Research Institute, TCE, Survival, BMS, BCMA, Biology, Pharmaceutical industry, Vaccine, Fine chemical, Cohort, RRMM

Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.
  • These data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.
  • While multiple myeloma remains a relentless disease, we continue to transform the multiple myeloma treatment paradigm by dramatically improving outcomes for every patient.
  • As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Integral Molecular Unveils Trispecific Molecules Targeting GPRC5D, BCMA, and CD3 for Multiple Myeloma

Retrieved on: 
Friday, November 3, 2023
Membrane, CD3, GPCR, RNA, Society for Immunotherapy of Cancer, GPRC5D, Doctor of Philosophy, Poster, Chicken, SITC, Immunotherapy, MPS, Antibody, Path integral molecular dynamics, Virus-like particle, Society, Patient, Integral, BCMA, DNA, Fine chemical, Vaccine

Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.

Key Points: 
  • Recent clinical data demonstrate that combination therapy of T cell engaging molecules individually targeting GPRC5D and BCMA on tumor cells offers unprecedented therapeutic benefits in relapsed/refractory multiple myeloma patients.
  • A trispecific antibody that simultaneously engages these molecules while activating T cells is expected to provide comparable and additional benefits as a monotherapy.
  • Integral Molecular's oncology drug discovery program has yielded a panel of high affinity bispecific and trispecific molecules targeting GPRC5D, a GPCR target with complex structural biology.
  • GPRC5D and other antibody assets from Integral Molecular are available for licensing.

Integral Molecular Secures Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets

Retrieved on: 
Thursday, October 5, 2023
Disease, Membrane, Health, Cancer, Antibody, Doctor of Philosophy, Integral, RNA, Multiple myeloma, SITC, Path integral molecular dynamics, GPRC5D, Primate, Virus-like particle, MPS, Eurosport 1, G protein-coupled receptor, Research, NIH, Chicken, Vaccine

Funding awarded by NIH enables Integral Molecular to discover antibodies against many of these targets.

Key Points: 
  • Funding awarded by NIH enables Integral Molecular to discover antibodies against many of these targets.
  • To enable better models of human disease, Integral Molecular has also received NIH funding to discover antibodies that target highly conserved proteins across species.
  • Integral Molecular will employ its MPS antibody discovery platform to discover antibodies for both initiatives.
  • Integral Molecular's strategy of generating antibodies in chickens is key for producing antibodies against conserved targets, a feat not easily achieved with conventional technologies.

Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day

Retrieved on: 
Thursday, September 14, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Bristol Myers Squibb, Janssen Pharmaceuticals, Lupus, Ruxolitinib, Probability, Eosinophilic esophagitis, Drug development, LPA1, Doctor of Philosophy, CD3, Target protein, Atrial fibrillation, GPRC5D, Cell therapy, Acute coronary syndrome, Medicine, BMY, Pulmonary fibrosis, BET, CAR, Neuroscience, NEX, Patient, Hematology, ROS1, IND Queens Boulevard Line, Biology, Canadian Aviation Regulations, Growth, Johnson & Johnson, Research and development, RRMM, BMS, R, FDA, NYSE, Idiopathic pulmonary fibrosis, BCMA, Disease, Fine chemical, Pharmaceutical industry, Vaccine

Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to provide insight into its robust pipeline supporting long-term sustainable growth.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) is today holding a Research and Development (R&D) Day in New York to discuss the company’s R&D strategy and capabilities and to provide insight into its robust pipeline supporting long-term sustainable growth.
  • “We are further enhancing our R&D engine to strengthen scientific leadership, accelerate our promising pipeline and drive increased productivity.
  • Key pipeline updates for the newly anticipated registrational assets include:
    CD19-directed NEX T cell therapy BMS-986353, expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus.
  • “Our research strategy will enable us to increase the number and quality of potentially transformational early-stage candidates, leveraging our differentiated research platforms, and accelerate the path from proof-of-concept to regulatory approval.”
    R&D Day takes place at 9 a.m.

Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

Retrieved on: 
Thursday, August 10, 2023
IND, GPRC5D, Telescopic sight, Pharmaceutical industry

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma (R/R MM).

Key Points: 
  • SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell Therapeutics Co., Ltd. ("Oricell") has received the green light for its Investigational New Drug (IND) application of OriCAR-017, a cutting-edge CAR-T cell therapy targeting GPRC5D to combat relapsed or refractory multiple myeloma (R/R MM).
  • This remarkable milestone not only marks the world's first tier GPRC5D-targeting CAR-T therapy approved in China but also underlines Oricells prowess as a frontrunner in the biotech industry.

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

Retrieved on: 
Thursday, August 10, 2023
Lymphocyte, Safety, Rash, Effectiveness, Janssen Pharmaceuticals, Patient, Fatigue, Disease, Tissue, REMS, University, Neutrophil, Diarrhea, GPRC5D, Xeroderma, Multiple myeloma, Hepatotoxicity, Bone marrow, Toxicity, Research, Ageusia, Independent Review Committee, Cytokine release syndrome, FDA, Headache, Skin, DSM-IV codes, Nail, CD3, CRS, Hypotension, Epithelium, Confidence interval, CR, Weight loss, Johnson & Johnson, Fever, ORR, Dysphagia, Mitigation, Xerostomia, SC, CI, B-cell maturation antigen, Clinical trial, Medicine, Physician, Upper respiratory tract infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, BCMA, Vaccine, Pharmaceutical industry, HORSHAM, Cytopenia, Bispecific monoclonal antibody, Dysgeusia, Infection

HORSHAM, Pa., Aug. 10, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TALVEY™ (talquetamab-tgvs), a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.1 This indication is approved under accelerated approval based on response rate and durability of response.1 Continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory trial(s).1 

Key Points: 
  • * "Patients at this stage of disease have a poor prognosis.
  • Talquetamab as a first-in-class therapy is a new option for patients with this difficult-to-treat blood cancer."
  • "Our team of scientists never settles in their determination to discover and develop effective therapies.
  • With the discovery of this new antigen, we continue to strive for research breakthroughs while remaining focused on delivering curative regimens in our commitment to eliminate cancer."